H J Kim1,2,3, M Zeidi1,2, D Bonciani1,2,4, S M Pena2, J Tiao1,2, S Sahu1,2, V P Werth1,2. 1. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, U.S.A. 2. Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, U.S.A. 3. Department of Dermatology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. 4. Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy.
Abstract
BACKGROUND: Interleukin (IL)-31 is implicated in pruritus associated with pruritic skin diseases like atopic dermatitis. Although pruritus is a prominent feature in dermatomyositis (DM), few studies have evaluated the pathogenesis of DM-associated itch. OBJECTIVES: To establish the prevalence of itch in DM, and to investigate the role of IL-31 in DM-related itch. METHODS: Pruritus and disease activity of DM were evaluated by a visual analogue scale (VAS) and the Cutaneous Disease and Activity Severity Index (CDASI), respectively. Expression of IL-31 and IL-31 receptor alpha (IL-31RA) in lesional DM, nonlesional DM and healthy control skin was evaluated by quantitative reverse-transcriptase polymerase chain reaction and immunofluorescence. Flow cytometry was performed on skin cells isolated from lesional DM skin to identify cellular sources of IL-31 in DM. RESULTS: Among 191 patients with DM, 50·8% had moderate-to-severe itch, and itch was correlated with increased cutaneous severity (r = 0·34). In patients with itchy DM, gene expression of IL31 and IL31RA in lesional skin was upregulated compared with nonlesional skin and healthy control skin. IL31 mRNA expression positively correlated with VAS itch score (r = 0·67). On immunofluorescence, immunoreactivity for IL-31 and IL-31RA was stronger in lesional skin. Flow cytometry showed that lesional DM skin contained significantly more IL-31-producing cells, and CD4+ cells were the most common cell type. Lenabasum, an emerging treatment for DM, significantly downregulated IL-31 from CpG-stimulated peripheral blood mononuclear cells. CONCLUSIONS: Increased skin IL-31 may play a role in DM-associated itch, and ongoing trials will evaluate the effects of systemic treatment on IL-31 and itch in DM. Published [2018]. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND:Interleukin (IL)-31 is implicated in pruritus associated with pruritic skin diseases like atopic dermatitis. Although pruritus is a prominent feature in dermatomyositis (DM), few studies have evaluated the pathogenesis of DM-associated itch. OBJECTIVES: To establish the prevalence of itch in DM, and to investigate the role of IL-31 in DM-related itch. METHODS:Pruritus and disease activity of DM were evaluated by a visual analogue scale (VAS) and the Cutaneous Disease and Activity Severity Index (CDASI), respectively. Expression of IL-31 and IL-31 receptor alpha (IL-31RA) in lesional DM, nonlesional DM and healthy control skin was evaluated by quantitative reverse-transcriptase polymerase chain reaction and immunofluorescence. Flow cytometry was performed on skin cells isolated from lesional DM skin to identify cellular sources of IL-31 in DM. RESULTS: Among 191 patients with DM, 50·8% had moderate-to-severe itch, and itch was correlated with increased cutaneous severity (r = 0·34). In patients with itchy DM, gene expression of IL31 and IL31RA in lesional skin was upregulated compared with nonlesional skin and healthy control skin. IL31 mRNA expression positively correlated with VAS itch score (r = 0·67). On immunofluorescence, immunoreactivity for IL-31 and IL-31RA was stronger in lesional skin. Flow cytometry showed that lesional DM skin contained significantly more IL-31-producing cells, and CD4+ cells were the most common cell type. Lenabasum, an emerging treatment for DM, significantly downregulated IL-31 from CpG-stimulated peripheral blood mononuclear cells. CONCLUSIONS: Increased skin IL-31 may play a role in DM-associated itch, and ongoing trials will evaluate the effects of systemic treatment on IL-31 and itch in DM. Published [2018]. This article is a U.S. Government work and is in the public domain in the USA.
Authors: T Miyagaki; M Sugaya; H Suga; H Ohmatsu; H Fujita; Y Asano; Y Tada; T Kadono; S Sato Journal: J Eur Acad Dermatol Venereol Date: 2012-03-09 Impact factor: 6.166
Authors: Elisha M Singer; Daniel B Shin; Leigh A Nattkemper; Bernice M Benoit; Rachel S Klein; Chuka A Didigu; Alison W Loren; Tzvete Dentchev; Maria Wysocka; Gil Yosipovitch; Alain H Rook Journal: J Invest Dermatol Date: 2013-05-22 Impact factor: 8.551
Authors: Krisztina Szegedi; Andreas E Kremer; Sanja Kezic; Marcel B M Teunissen; Jan D Bos; Rosalie M Luiten; Pieter C Res; Maritza A Middelkamp-Hup Journal: Exp Dermatol Date: 2012-06 Impact factor: 3.960
Authors: Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross Journal: Nat Immunol Date: 2004-06-06 Impact factor: 25.606
Authors: Josef Symon S Concha; Aikaterini Patsatsi; Ann Marshak-Rothstein; Ming-Lin Liu; Animesh A Sinha; Lela A Lee; Joseph F Merola; Ali Jabbari; Johann E Gudjonsson; François Chasset; Paul Jarrett; Benjamin Chong; Lisa Arkin; Anthony P Fernandez; Marzia Caproni; Steven A Greenberg; Hee Joo Kim; David R Pearson; Alisa Femia; Ruth Ann Vleugels; David Fiorentino; Manabu Fujimoto; Joerg Wenzel; Victoria P Werth Journal: J Invest Dermatol Date: 2018-09-19 Impact factor: 8.551
Authors: Jana Maria Nemmer; Marcus Kuchner; Angeliki Datsi; Péter Oláh; Valérie Julia; Ulrike Raap; Bernhard Homey Journal: Front Med (Lausanne) Date: 2021-02-10
Authors: Robert Spiera; Laura Hummers; Lorinda Chung; Tracy M Frech; Robyn Domsic; Vivien Hsu; Daniel E Furst; Jessica Gordon; Maureen Mayes; Robert Simms; Robert Lafyatis; Viktor Martyanov; Tammara Wood; Michael L Whitfield; Scott Constantine; Elizabeth Lee; Nancy Dgetluck; Barbara White Journal: Arthritis Rheumatol Date: 2020-07-17 Impact factor: 10.995